Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.

Ha, So-Young; Kang, Dong-Won; Jung, Hye-In; Lee, Eui-Kyung; Park, Mi-Hai

Ha, So-Young; Kang, Dong-Won; Jung, Hye-In; Lee, Eui-Kyung; Park, Mi-Hai.

Affiliation

Ha SY; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Kang DW; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Jung HI; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Lee EK; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Park MH; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.

Int J Environ Res Public Health ; 19(7)2022 03 30.

Article in En | MEDLINE | ID: mdl-35409788

Subject(s)

Drug Costs; Nivolumab; Budgets; Cost-Benefit Analysis; Immunotherapy

Key words

immunotherapy; indication-based pricing; multi-indication; value-based pricing; weighted-average pricing

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Costs / Nivolumab Type of study: Health_economic_evaluation Language: En Journal: Int J Environ Res Public Health Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google